Enhancing radiation response by a second-generation TRAIL receptor agonist using a new in vitro organoid model system.
Conclusions: In a new, clinically relevant CRC-organoid model system we demonstrated a more than additive combined effect between the second-generation TRAIL receptor agonist APG-880 and radiation. PMID: 32577539 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - June 26, 2020 Category: Cancer & Oncology Authors: Zerp SF, Bibi Z, Verbrugge I, Voest EE, Verheij M Tags: Clin Transl Radiat Oncol Source Type: research

Stoma closure and reinforcement (SCAR): A study protocol for a pilot trial.
Abstract A quality metric for centers performing rectal cancer surgery is a high percentage of sphincter sparing procedures. These procedures often involve temporary bowel diversion to minimize the complications of an anastomotic leak. The most common strategy is a diverting loop ileostomy which is then closed after completion of adjuvant therapy or the patient recovers from surgery. Loop ileostomy is not without complications and the closure is complicated by a one in three chance of incisional hernia development. Strategies to prevent this problem have been designed using a variety of techniques with and without...
Source: Clinical Colorectal Cancer - June 26, 2020 Category: Cancer & Oncology Authors: Goldwag JL, Wilson LR, Ivatury SJ, Pauli EM, Tsapakos MJ, Wilson MZ Tags: Contemp Clin Trials Commun Source Type: research

Proven Strategies for Increasing Adherence to Colorectal Cancer Screening.
This article reviews the current available evidence about interventions to increase adherence to CRC screening. PMID: 32439077 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Butterly LF Tags: Gastrointest Endosc Clin N Am Source Type: research

What Is Organized Screening and What Is Its Value?
Abstract Most screening in the United States occurs in an opportunistic fashion, although organized screening occurs in some integrated health care systems. Organized colorectal cancer (CRC) screening consists of an explicit screening policy, defined target population, implementation team, health care team for clinical care delivery, quality assurance infrastructure, and method for identifying cancer outcomes. Implementation of an organized screening program offers opportunities to systematically assess the success of the program and develop interventions to address identified gaps in an effort to optimize CRC out...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Dominitz JA, Levin TR Tags: Gastrointest Endosc Clin N Am Source Type: research

Colorectal Cancer Screening Decisions in the Opportunistic Setting.
Abstract Colorectal cancer incidence and mortality have decreased in the United States in recent decades, largely through opportunistic screening. Although certain organizations have improved internal screening rates by implementing programmatic screening, most of the United States undergoes opportunistic screening. Much effort and resources have been expended comparing screening tests to determine the most effective; however, deeper analysis of the US population has revealed subsets of ethnicities may be grossly underscreened. The most effective screening test remains the test that is completed and adhered to, an...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Han A, Maratt J, Kahi C Tags: Gastrointest Endosc Clin N Am Source Type: research

Risk Stratification Strategies for Colorectal Cancer Screening: From Logistic Regression to Artificial Intelligence.
Abstract Risk stratification is a system by which clinically meaningful separation of risk is achieved in a group of otherwise similar persons. Although parametric logistic regression dominates risk prediction, use of nonparametric and semiparametric methods, including artificial neural networks, is increasing. These statistical-learning and machine-learning methods, along with simple rules, are collectively referred to as "artificial intelligence" (AI). AI requires knowledge of study validity, understanding of model metrics, and determination of whether and to what extent the model can and should be app...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Imperiale TF, Monahan PO Tags: Gastrointest Endosc Clin N Am Source Type: research

Colorectal Cancer in Persons Under Age 50: Seeking Causes and Solutions.
Abstract Early onset colorectal cancer (EOCRC) refers to colorectal cancer (CRC) in individuals under age 50. Although the incidence and mortality due to later onset CRC (≥50 years) has been declining over several decades, both are increasing in those under 50. EOCRC is more likely to occur in the distal colon and rectum. There are some unique pathologic and genetic features to these tumors; they are not usually associated with a germline mutation in a gene that predisposes to cancer, and at least some may have a distinct pathogenesis. Initiating CRC screening at an earlier age (40-45 years of age) would p...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Patel SG, Boland CR Tags: Gastrointest Endosc Clin N Am Source Type: research

Colorectal Cancer Screening for the Serrated Pathway.
Abstract Serrated polyps are classified into hyperplastic polyps, sessile serrated adenomas/polyps, and traditional serrated adenomas. Although all serrated polyps share characteristic colonic crypts serrations, distinguishing hyperplastic polyps from sessile serrated adenomas/polyps is challenging. Traditional serrated adenomas are cytologically dysplastic lesions; sessile serrated adenomas/polyps develop cytologic dysplasia as they progress to colorectal cancer. A flat and pale appearance of serrated polyps may make detection difficult. Endoscopic mucosal resection has higher rates of complete resection. Close s...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Anderson JC, Srivastava A Tags: Gastrointest Endosc Clin N Am Source Type: research

Cost-Effectiveness of Current Colorectal Cancer Screening Tests.
Abstract Cost-effectiveness analysis compares benefits and costs of different interventions to inform decision makers. Alternatives are compared based on an incremental cost-effectiveness ratio reported in terms of cost per quality-adjusted life-year gained. Multiple cost-effectiveness analyses of colorectal cancer (CRC) screening have been performed. Although regional epidemiology of CRC, relevant screening strategies, regional health system, and applicable medical costs in local currencies differ by country and region, several overarching points emerge from literature on cost-effectiveness of CRC screening. Cost...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Ladabaum U Tags: Gastrointest Endosc Clin N Am Source Type: research

The National Colorectal Cancer Roundtable: Past Performance, Current and Future Goals.
Abstract The National Colorectal Cancer Roundtable (NCCRT) is an organization of organizations with staffing, funding and leadership provided by the American Cancer Society (ACS) and guidance and funding by the Centers for Disease Control and Prevention (CDC). In 2014, ACS, CDC, and the NCCRT launched the 80% by 2018 campaign. This highly successful initiative activated hundreds of organizations to prioritize colorectal cancer screening, disseminated smart, evidence-based interventions, and ultimately led to 9.3 million more Americans being up to date with screening compared with the precampaign rate. It's new cam...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Wender R, Brooks D, Sharpe K, Doroshenk M Tags: Gastrointest Endosc Clin N Am Source Type: research

Fecal Immunochemical Test: The World's Colorectal Cancer Screening Test.
This article reviews current understanding of FIT performance as a 1-time test and when applied programmatically. It outlines how to apply the test at the patient level and track performance at the program level. Future prospects for FIT application are highlighted. PMID: 32439085 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Robertson DJ, Selby K Tags: Gastrointest Endosc Clin N Am Source Type: research

The Case for High-Quality Colonoscopy Remaining a Premier Colorectal Cancer Screening Strategy in the United States.
Abstract Most colorectal cancer screening in the United States occurs in the opportunistic setting, where screening is initiated by a patient-provider interaction. Colonoscopy provides the longest-interval protection, and high-quality colonoscopy is ideally suited to the opportunistic setting. Both detection and colonoscopic resection have improved as a result of intense scientific investigation. Further improvements in detection are expected with the introduction of artificial intelligence programs into colonoscopy platforms. We may expect recommended intervals or colonoscopy after negative examinations performed...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Rex DK Tags: Gastrointest Endosc Clin N Am Source Type: research

Quality in Colorectal Cancer Screening with Colonoscopy.
Abstract The goal of colorectal cancer (CRC) screening with colonoscopy is to minimize CRC with minimal risk and cost. In order to continuously improve the quality of colonoscopy, different outcomes must be measured. For this topic, the priority indicators to be measured are (1) frequency of scheduling colonoscopy at appropriate interval based on current guidelines; (2) frequency of identifying adenomas in average-risk individuals undergoing their first screening colonoscopy; and, (3) providing guideline-consistent recommendations for repeat colonoscopy after the procedure. PMID: 32439087 [PubMed - in process...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Schoenfeld P Tags: Gastrointest Endosc Clin N Am Source Type: research

Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions.
Abstract After 2 screen-setting studies showing high sensitivity for colorectal cancer and advanced precancerous lesions, multitarget stool DNA testing was endorsed by the US Preventative Services Task Force as a first-line colorectal cancer screening test. Uptake has increased exponentially since approval by the US Food and Drug Administration and Centers for Medicare and Medicaid Services. Adherence to testing is approximately 70%. Patients with positive results have high diagnostic colonoscopy completion rates in single-center studies. The positive predictive value for colorectal neoplasia in postapproval studi...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Kisiel JB, Eckmann JD, Limburg PJ Tags: Gastrointest Endosc Clin N Am Source Type: research

Update on Flexible Sigmoidoscopy, Computed Tomographic Colonography, and Capsule Colonoscopy.
This article reviews alternative colorectal cancer (CRC) screening tests, including flexible sigmoidoscopy (FS), computed tomography (CT) colonography, and colon capsule endoscopy. FS has abundant and convincing evidence supporting its use for CRC screening and is a commonly used CRC test worldwide. CT colonography has demonstrated convincing results for CRC screening, but concerns regarding cost, accuracy for flat or sessile neoplasia, reproducibility, extracolonic findings, and lack of coverage have limited its use and development. Colon capsule endoscopy has demonstrated encouraging results for polyp detection in averag...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Chung SW, Hakim S, Siddiqui S, Cash BD Tags: Gastrointest Endosc Clin N Am Source Type: research

Evidenced-Based Screening Strategies for a Positive Family History.
Abstract The most commonly recognized high-risk group for colorectal cancer (CRC) is individuals with a positive family history. It is generally recognized that those with a first-degree relative (FDR) with CRC are at a 2-fold or higher risk of CRC or advanced neoplasia. FDRs of patients with advanced adenomas have a similarly increased risk. Accordingly, all major US guidelines recommend starting CRC screening by age 40 in these groups. Barriers to screening this group include patient lack of knowledge on family and polyp history, provider limitations in collecting family history, and insufficient application of ...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Kolb JM, Ahnen DJ, Samadder NJ Tags: Gastrointest Endosc Clin N Am Source Type: research

Colorectal Cancer Screening: Where We Are and Moving Forward.
PMID: 32439092 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Lightdale CJ Tags: Gastrointest Endosc Clin N Am Source Type: research

Colorectal Cancer Screening.
PMID: 32439093 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Rex DK Tags: Gastrointest Endosc Clin N Am Source Type: research

Goals-to-Discharge Patient Checklist: Implementing a Program to Optimize Recovery After Surgery for Patients With Colorectal Cancer.
Abstract Fast-track or enhanced recovery after surgery (ERAS) pathways are evidence-based perioperative guides that promote stress reduction and earlier return to function following surgery. They emphasize preoperative counseling, nutrition optimization, analgesia standardization, fluid and electrolyte balance, minimally invasive approaches, and early ambulation. Although ERAS pathways were implemented in 2016 on a 43-bed postoperative colorectal medical-surgical unit, inpatient stays remained beyond the projected two-day length of stay (LOS). A quality improvement team was formed and an eight-week pilot project w...
Source: Clinical Colorectal Cancer - May 24, 2020 Category: Cancer & Oncology Authors: Trocchia Mattessich N Tags: Clin J Oncol Nurs Source Type: research

Using low concentration sodium hypochlorite to improve colorectal surgical specimen lymph node harvest.
Abstract Lymph node (LN) retrieval is a critical procedure to determine the pathological stage and adjuvant therapy for colorectal cancer. The present study aimed to recommend a novel method by using sodium hypochlorite to improve colorectal surgical specimen LN harvest. Dissolving time of mesenteric LNs and fat tissue was firstly investigated in different concentrations of sodium hypochlorite. In the sodium hypochlorite group, 65 patients with colorectal cancer who underwent curative surgery were included. After standard manual gross dissection, the mesenteric tissue was subsequently immersed in 1% sodium hypochl...
Source: Clinical Colorectal Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Yu N, Liu H, Li J, Chen S Tags: Mol Clin Oncol Source Type: research

Clinicopathological features and maternal and foetal management of pregnancy-complicating Krukenberg tumours.
Abstract Krukenberg tumours are not uncommon, but pregnancy-complicating Krukenberg tumours are rare. To identify management strategies of pregnancies with Krukenberg tumours, the medical records of patients treated at Peking Union Medical College Hospital over the past 20 years were collected and analysed. Four patients were enrolled. The primary tumour sites were the stomach and colorectal region. Three patients presented with obvious and severe gastrointestinal symptoms at 11-18 weeks of gestation, and their symptoms gradually developed into physiological signs associated with malignancy. Three patients underwe...
Source: Clinical Colorectal Cancer - April 28, 2020 Category: Cancer & Oncology Authors: Zhang J, Peng P, Cao D, Yang J, Shen K Tags: Mol Clin Oncol Source Type: research

LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGF β signaling in colorectal cancer.
LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFβ signaling in colorectal cancer. J Cancer Res Clin Oncol. 2020 May;146(5):1205-1215 Authors: Javanmard AR, Dokanehiifard S, Bohlooli M, Soltani BM Abstract Non-coding RNAs (ncRNAs) are reported to be regulators of signaling pathways that are involved in colorectal cancer (CRC) progression. Aiming at finding ncRNAs (miRNAs) that are differentially expressed in tumor versus normal colorectal tissue samples, online RNA-seq data were analyzed. Of between 18 candidate miRNAs, hsa-miR-29b-1 (miR-29b-1) represented the highest fold change...
Source: Clinical Colorectal Cancer - April 18, 2020 Category: Cancer & Oncology Authors: Javanmard AR, Dokanehiifard S, Bohlooli M, Soltani BM Tags: J Cancer Res Clin Oncol Source Type: research

Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study.
Abstract BACKGROUND: Hepatic artery infusion (HAI) and drug selection by liquid biopsy precision oncotherapy are under investigation for the multidisciplinary treatment of unresectable colorectal liver metastases (CRCLM) in progression after systemic therapy. Here, we compare the safety and efficacy of third-line HAI followed by target therapy with drug regimes selected by liquid biopsy precision oncotherapy to third-line systemic therapy with drug regimes selected partly by tissue biopsy precision oncotherapy, in a retrospective real-life study of 106 unresectable CRCLM patients. METHODS: Drug regimens for H...
Source: Clinical Colorectal Cancer - April 18, 2020 Category: Cancer & Oncology Authors: Guadagni S, Clementi M, Mackay AR, Ricevuto E, Fiorentini G, Sarti D, Palumbo P, Apostolou P, Papasotiriou I, Masedu F, Valenti M, Giordano AV, Bruera G Tags: J Cancer Res Clin Oncol Source Type: research

A meta-analysis of serological thymidine kinase 1 as a marker for colorectal benign and malignant tumor risk assessment.
Abstract The present study investigated whether a concentration of serum thymidine kinase 1 (STK1p) could be used to distinguish between healthy individuals, patients with colorectal benign tumors and individuals with colorectal cancer (CRC). The effectiveness of surgery on patients with CRC was monitored. A total of 20 publications containing patients with CRC (n=1,836), patients with colorectal benign tumors (n=774) and healthy controls (n=1,701) were analysed in the present meta-analysis. The publications were collected from PubMed, Embase, CENTRAL, CNKI, Wanfang, VIP and SinoMed databases from January 1, 2009 ...
Source: Clinical Colorectal Cancer - April 8, 2020 Category: Cancer & Oncology Authors: Dang L, Ma H, Hei A, Xu S, Zhou J, He E, Skog S Tags: Mol Clin Oncol Source Type: research

Examination of the expression levels of MACC1, Filamin A and FBXW7 genes in colorectal cancer patients.
CONCLUSION: To our knowledge, our study is the first study to investigate the effects of Xelox treatment on the expression levels of MACC1, FBXW7 and FLNA genes in non-metastatic colorectal cancer patients in Turkey. PMID: 32232196 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - April 3, 2020 Category: Cancer & Oncology Authors: Yesilkaya F, Tastekin D, Saadoni HA, Ergen A, Pence S Tags: North Clin Istanb Source Type: research

Preoperative chemotherapy in colorectal cancer patients with synchronous liver metastasis.
Abstract The response to preoperative chemotherapy is useful for predicting prognosis in unresectable and resectable disease. However, the prognostic benefit of chemotherapy prior to hepatectomy in patients with colorectal carcinoma and resectable or marginally resectable liver metastases remains unclear. The present study investigated the effect of preoperative chemotherapy on the prognosis of patients with colorectal cancer and resectable or marginally resectable synchronous liver metastasis. A total of 106 patients were retrospectively reviewed, who underwent hepatectomy for colorectal metastasis. The prognosis...
Source: Clinical Colorectal Cancer - March 21, 2020 Category: Cancer & Oncology Authors: Ichikawa N, Kamiyama T, Yokoo H, Homma S, Maeda Y, Shinohara T, Tsuruga Y, Kazui K, Iijima H, Yoshida T, Taketomi A Tags: Mol Clin Oncol Source Type: research

Robotic Colorectal Surgery.
Abstract The role of robotics in colon and rectal surgery has been established as an important and effective tool for the surgeon. Its inherent technologies have provided for increased visualization and ease of dissection in the minimally invasive approach to surgery. The value of the robot is apparent in the more challenging aspects of colon and rectal procedures, including the intracorporeal anastomosis for right colectomies and the low pelvic dissection for benign and malignant diseases. PMID: 32169183 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 15, 2020 Category: Cancer & Oncology Authors: Addison P, Agnew JL, Martz J Tags: Surg Clin North Am Source Type: research

Block of proliferation 1 promotes cell migration and invasion in human colorectal cancer cells via the JNK pathway.
In this study, the results of immunohistochemistry showed that BOP1 was upregulated in our cohort of CRC patients. BOP1 knockdown inhibited the migration and invasion of CRC cells, confirmed by the downregulation of the mRNA levels of MMP-2 and MMP-9. The overexpression of BOP1 in CRC cells exerted the opposite effect. SP600125, an inhibitor of JNK signaling, partially abolished the BOP1 overexpression-mediated increase in the migratory and invasive ability of CRC cells. Our results indicated that BOP1 is an important regulator of CRC cell invasion and migration, predominantly through the JNK signaling pathway. PMID: ...
Source: Clinical Colorectal Cancer - March 13, 2020 Category: Cancer & Oncology Authors: Chen X, Zhao Y Tags: J Clin Lab Anal Source Type: research

Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review.
ert L, Hendrix RJ, Hays J, Abdel-Misih S, Cloyd JM Abstract Cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with improved survival for patients with colorectal peritoneal metastases (CR-PM). However, the role of neoadjuvant chemotherapy (NAC) prior to CRS-HIPEC is poorly understood. A retrospective review of adult patients with CR-PM who underwent CRS+/-HIPEC from 2000-2017 was performed. Among 298 patients who underwent CRS+/-HIPEC, 196 (65.8%) received NAC while 102 (34.2%) underwent surgery first (SF). Patients who received NAC had lower peritoneal can...
Source: Clinical Colorectal Cancer - March 10, 2020 Category: Cancer & Oncology Authors: Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Lee B, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Dhar V, Lam Tags: J Clin Med Source Type: research

MicroRNAs that regulate PTEN as potential biomarkers in colorectal cancer: a systematic review.
CONCLUSIONS: The loss of PTEN may be a diagnostic factor for CRC patients. The above-mentioned miRNAs may function as oncogenes in CRC and represent potential targets for CRC therapy. However, further prospective clinical studies are necessary. PMID: 32146564 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 7, 2020 Category: Cancer & Oncology Authors: Liu J, Ke F, Chen T, Zhou Q, Weng L, Tan J, Shen W, Li L, Zhou J, Xu C, Cheng H, Zhou J Tags: J Cancer Res Clin Oncol Source Type: research

Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study.
CONCLUSION: This study provides evidence suggesting bevacizumab and cetuximab lead to similar effectiveness outcomes in mCRC, except for right-sided tumours, where cetuximab seemed to show considerably poorer outcomes. Further research is needed to confirm these results. PMID: 32144533 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 6, 2020 Category: Cancer & Oncology Authors: Marques RP, Godinho AR, Heudtlass P, Pais HL, Quintela A, Martins AP Tags: J Cancer Res Clin Oncol Source Type: research

Will They Show? Predictors of Nonattendance for Scheduled Screening Colonoscopies at a Safety Net Hospital.
CONCLUSIONS: Specific predictors for scheduled screening colonoscopy nonattendance at a safety net hospital can be identified. These findings can be used to tailor community-based interventions to improve colorectal cancer screening rates. PMID: 32149821 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 6, 2020 Category: Cancer & Oncology Authors: O'Neil J, Winter E, Hemond C, Fass R Tags: J Clin Gastroenterol Source Type: research

SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of Wnt/ β-catenin signaling pathway via miR92b-3p/FZD10 in nasopharyngeal carcinoma cells.
CONCLUSIONS: This study delineates SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of the Wnt/β-catenin signaling pathway via miR92b-3p/FZD10 in nasopharyngeal carcinoma cells and, hence, SEPT9_v2 may be a promising therapeutic target and biomarker for nasopharyngeal carcinoma. PMID: 32138771 [PubMed - in process] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Jiang Y, Liu L, Xiang Q, He X, Wang Y, Zhou D, Zou C, Chen Q, Peng M, He J, Jiang X, Xiang T, Yang Y Tags: Clin Epigenetics Source Type: research

Colorectal cancer statistics, 2020.
Abstract Colorectal cancer (CRC) is the second most common cause of cancer death in the United States. Every 3 years, the American Cancer Society provides an update of CRC occurrence based on incidence data (available through 2016) from population-based cancer registries and mortality data (through 2017) from the National Center for Health Statistics. In 2020, approximately 147,950 individuals will be diagnosed with CRC and 53,200 will die from the disease, including 17,930 cases and 3,640 deaths in individuals aged younger than 50 years. The incidence rate during 2012 through 2016 ranged from 30 (per 10...
Source: Clinical Colorectal Cancer - March 5, 2020 Category: Cancer & Oncology Authors: Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A Tags: CA Cancer J Clin Source Type: research

Colorectal cancer in the United States and a review of its heterogeneity among Asian American subgroups.
Abstract Colorectal cancer is the third most common cancer in the United States. Established risk factors include older age, unhealthy lifestyle (high consumptions of red/preserved meat, low consumptions of fruit and vegetables, smoking, high alcohol consumption, and lack of physical activities), personal and family medical histories and low socioeconomic status (low insurance coverage, education and income). Asian American subgroups vary significantly in terms of culture, socioeconomic status, and health behaviors, yet most registries and researches aggregate all Asian Americans as one group. In this review, we s...
Source: Clinical Colorectal Cancer - March 4, 2020 Category: Cancer & Oncology Authors: Gu M, Thapa S Tags: Asia Pac J Clin Oncol Source Type: research

Variations in clinical features and oncologic behaviors of T1 colorectal cancer according to tumor location.
Abstract BACKGROUND: Different genetic characteristics according to tumor location result in variations in survival rates and treatment responses in advanced colorectal cancer (CRC). However, the effects of tumor location during early CRC are still unclear. METHODS: Patients with T1 CRC treated between 2003 and 2019 were enrolled from a prospectively collected database. Patients were once divided into four groups, then combined into two groups (right- and left-sided CRC) according to the tumor location, and clinical features and oncologic behaviors were compared. RESULTS: In total, 458 patients were anal...
Source: Clinical Colorectal Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Ouchi A, Toriyama K, Kinoshita T, Tanaka T, Shimizu Y, Niwa Y, Tajika M, Komori K Tags: Int J Clin Oncol Source Type: research

Challenges of improving treatment outcomes for colorectal and anal cancers in Japan: the Colorectal Cancer Study Group (CCSG) of the Japan Clinical Oncology Group (JCOG).
Abstract Colorectal cancer is a major public health concern in Japan. While early-stage colorectal adenocarcinoma treatment entails radical resection of the primary tumor, the importance of perioperative treatment is growing as physicians seek to further improve treatment outcomes. For anal squamous cell carcinoma, definitive chemoradiotherapy is superior to radical surgery in terms of improved patient quality of life. The Colorectal Cancer Study Group of the Japanese Clinical Oncology Group was established in 2001 and has worked to provide answers to common clinical questions and improve treatment outcomes for co...
Source: Clinical Colorectal Cancer - March 2, 2020 Category: Cancer & Oncology Authors: Ouchi A, Shida D, Hamaguchi T, Takashima A, Ito Y, Ueno H, Ishiguro M, Takii Y, Ikeda S, Ohue M, Fujita S, Shiozawa M, Kataoka K, Ito M, Tsukada Y, Akagi T, Inomata M, Shimada Y, Kanemitsu Y Tags: Jpn J Clin Oncol Source Type: research

Application of the Adaptive Validation Substudy Design to Colorectal Cancer Recurrence.
Conclusion: In this proof of concept application of the adaptive validation study design for outcome misclassification, we demonstrated the ability of the method to accurately determine when sufficient validation data have been collected. This method serves as a novel validation substudy design for prospectively collected data with simultaneous implementation of a validation study. PMID: 32099477 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 28, 2020 Category: Cancer & Oncology Authors: Collin LJ, Riis AH, MacLehose RF, Ahern TP, Erichsen R, Thorlacius-Ussing O, Lash TL Tags: Clin Epidemiol Source Type: research

Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
Abstract Objective: We performed a meta-analysis to quantify the overall incidence and risk of proteinuria associated with five newly approved VEGFR-TKIs (regorafenib, vandetanib, cabozantinib, lenvatinib, axitinib) in cancer patients.Methods: Pubmed, Embase, ASCO abstracts and ESMO abstracts were searched to identify relevant studies. Overall incidence rates, relative risk (RR), and 95% confidence intervals (CI) were estimated using random or fixed effects models according to the heterogeneity of included studies.Results: A total of 9,446 patients from 20 RCTs were included for the meta-analysis. The use of newly...
Source: Clinical Colorectal Cancer - February 27, 2020 Category: Cancer & Oncology Authors: Zhang W, Feng LJ, Teng F, Li YH, Zhang X, Ran YG Tags: Expert Rev Clin Pharmacol Source Type: research

Patient-derived xenograft models for personalized medicine in colorectal cancer.
Abstract Establishing superior preclinical models is critical for translational cancer research owing to the high failure rates of novel therapeutics in clinical studies. Even though cell line-derived xenograft models are easy to create, they have numerous limitations since these models do not represent the distinctive features of each cancer patient adequately. To circumvent the discrepancies between xenograft models and tumors, patient-derived xenograft (PDX) models have been developed. These models are established through the engraftment of tissue from a patient's tumor into an immune-deficient mouse, which pre...
Source: Clinical Colorectal Cancer - February 25, 2020 Category: Cancer & Oncology Authors: Xie J, Lin Y Tags: Clin Exp Med Source Type: research

Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer.
Conclusion: Cytokine-induced killer cell immunotherapy combined with first-line chemotherapy could significantly improve the OS and PFS of patients with mCRC, particularly for patients with metastatic colon cancer. PMID: 32076550 [PubMed] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 23, 2020 Category: Cancer & Oncology Authors: Pan QZ, Gu JM, Zhao JJ, Tang Y, Wang QJ, Zhu Q, Song MJ, Li YQ, He J, Chen SP, Weng DS, Xia JC Tags: Clin Transl Immunology Source Type: research

The safety and effectiveness of carbon nanoparticles suspension in tracking lymph node metastases of colorectal cancer: a prospective randomized controlled trial.
This study was to evaluate the safety and effectiveness of carbon nanoparticles suspension in tracking lymph node metastases of colorectal cancer. METHODS: Eligible patients diagnosed with stages I-III colorectal cancer in Fudan University Shanghai Cancer Center between 1 May 2017 and 31 May 2018 fulfilling the inclusion criteria were included in this prospective randomized controlled study. All the patients were randomly allocated to two groups: the nanocarbon group and the control group. Patients' clinicopathological characteristics were compared between the nanocarbon group and the control group. For continuous var...
Source: Clinical Colorectal Cancer - February 21, 2020 Category: Cancer & Oncology Authors: Wang R, Mo S, Liu Q, Zhang W, Zhang Z, He Y, Cai G, Li X Tags: Jpn J Clin Oncol Source Type: research

Colorectal cancer-derived exosomal miR-106b-3p promotes metastasis by downregulating DLC-1 expression.
Abstract Cancer-derived exosomal miRNAs play an important role in the development of metastasis, but the effects and underlying mechanisms remain unclear. In the present study, we investigated the miRNA expression profiles of 5 paired serum exosomal samples from metastatic colorectal cancer (mCRC) and non-mCRC patients via RNA sequencing. After we evaluated the differentially expressed miRNAs in 80 CRC patients, miR-106b-3p was selected as a metastasis-associated miRNA of CRC. We showed that the expression level of serum exosomal miR-106b-3p was significantly higher in CRC patients with metastasis than those witho...
Source: Clinical Colorectal Cancer - February 17, 2020 Category: Cancer & Oncology Authors: Liu H, Liu Y, Sun P, Leng K, Xu Y, Mei L, Han P, Zhang B, Yao K, Li C, Bai J, Cui B Tags: Clin Sci (Lond) Source Type: research

No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial.
CONCLUSIONS: Based on an ancillary study of data from the VITAL trial, daily vitamin D supplementation (2000 IU) was not associated with risk of colorectal cancer precursors in average-risk adults not selected for vitamin D insufficiency. A potential benefit for individuals with low baseline level of vitamin D requires further investigation. ClinicalTrials.gov number: NCT01169259. PMID: 32062040 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Song M, Lee IM, Manson JE, Buring JE, Dushkes R, Gordon D, Walter J, Wu K, Chan AT, Ogino S, Fuchs CS, Meyerhardt JA, Giovannucci EL Tags: Clin Gastroenterol Hepatol Source Type: research

Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
CONCLUSIONS: Stereotactic body radiation therapy can be considered an effective treatment for the management of liver and lung metastases from CRC. With RPA, we identified prognostic risk class to define patients who could benefit the most from SBRT. PMID: 32056005 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Franzese C, Comito T, Franceschini D, Loi M, Clerici E, Navarria P, De Rose F, Di Brina L, Mancosu P, Reggiori G, Tomatis S, Scorsetti M Tags: J Cancer Res Clin Oncol Source Type: research

Restoration of MARCK enhances chemosensitivity in cancer.
CONCLUSIONS: Cells devoid of MARCKS function showed incomplete ABCB1 internalization, leading to higher ABCB1 activity enhancing chemoresistance. Vice versa our data suggest the prevention of MARCKS inhibition by reversing hyperphosphorylation or genomic restoration after deletion as two promising approaches to overcome tumor cell resistance towards chemotherapeutic ABCB1 substrates. PMID: 32056006 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 13, 2020 Category: Cancer & Oncology Authors: Wenzel T, Büch T, Urban N, Weirauch U, Schierle K, Aigner A, Schaefer M, Kalwa H Tags: J Cancer Res Clin Oncol Source Type: research

THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition.
CONCLUSIONS: By collecting the omics data with functional studies, the present results reveal that THBS1 facilitates colorectal liver metastasis through promoting epithelial-mesenchymal transition. This understanding of molecular roles of THBS1 in CRLM may be promising to develop targeted therapies to prolong survival in CRC patients. PMID: 32052380 [PubMed - as supplied by publisher] (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - February 12, 2020 Category: Cancer & Oncology Authors: Liu X, Xu D, Liu Z, Li Y, Zhang C, Gong Y, Jiang Y, Xing B Tags: Clin Transl Oncol Source Type: research

Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer.
Abstract BACKGROUND: Accumulating evidence demonstrated immune/inflammation-related implications of basophils in affecting tissue microenvironment that surrounded a tumor, and this study aimed to elucidate the clinical value of serum basophil count level. METHODS: Between December 2007 and September 2013, 1029 patients diagnosed with stage I-III CRC in Fudan University Shanghai Cancer Center meeting the essential criteria were identified. The Kaplan-Meier method was used to construct the survival curves. Several Cox proportional hazard models were constructed to assess the prognostic factors. A simple predict...
Source: Clinical Colorectal Cancer - February 10, 2020 Category: Cancer & Oncology Authors: Liu Q, Luo D, Cai S, Li Q, Li X Tags: Clin Transl Med Source Type: research

Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis.
Abstract PURPOSE: Several studies have evaluated surgical resection of pulmonary metastases as a standard treatment option for colorectal cancer (CRC) patients with resectable pulmonary metastases. However, the role of peri-operative chemotherapy after complete resection of pulmonary metastases from CRC patients is still controversial. This systematic review and meta-analysis is aimed to investigate the clinical efficacy of peri-operative chemotherapy after resection of CRC pulmonary metastases. METHODS: PubMed, the Cochrane Library databases, and Embase were searched for studies evaluating the effect of...
Source: Clinical Colorectal Cancer - February 8, 2020 Category: Cancer & Oncology Authors: Li Y, Qin Y Tags: J Cancer Res Clin Oncol Source Type: research

Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients.
We examined area under the unbound plasma concentration-time curve (AUCu) to these compounds to establish pharmacokinetic bases for individualized dosing-strategies. The plasma protein binding of M-2 and M-5 was approximately 10-fold lower than that of regorafenib, whereas AUCu values for active metabolites on both days 1 and 15 were significantly higher than that of regorafenib. Patients with higher AUCu values of M-2 or M-5 on day 1 showed significantly shorter progression-free survival than others, likely due, at least in part to treatment discontinuation as a result of adverse events, especially occurred during first c...
Source: Clinical Colorectal Cancer - February 8, 2020 Category: Cancer & Oncology Authors: Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y Tags: Clin Pharmacol Ther Source Type: research